Translating genomic biomarkers into clinically useful diagnostics

Expert Review of Molecular Diagnostics

Volumn 6, Issue 2, 2006, Pages 179-191

  Ginsburg, Geoffrey S ^a   Haga, Susanne B ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Genomic biomarker; Microarray; Proteomics

Indexed keywords

BIOLOGICAL MARKER; DNA; PROTEIN;

CHROMOSOME ANALYSIS; CLINICAL LABORATORY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE MARKER; EPIGENETICS; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH PRACTITIONER; HUMAN; MEDICAL EDUCATION; MEDICAL RESEARCH; NUTRIGENOMICS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; RECURRENT DISEASE; REVIEW; RNA TRANSLATION; BIOLOGICAL MODEL; BIOLOGY; CLINICAL MEDICINE; CLINICAL TRIAL; CYTOGENETICS; GENETIC PREDISPOSITION; GENOME; GENOMICS; MEDICAL ETHICS; METHODOLOGY; PHARMACOGENETICS; PRIVACY; RISK ASSESSMENT;

BIOLOGICAL MARKERS; CLINICAL MEDICINE; CLINICAL TRIALS; COMPUTATIONAL BIOLOGY; CYTOGENETICS; ETHICS, MEDICAL; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOMICS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR DIAGNOSTIC TECHNIQUES; PHARMACOGENETICS; PRIVACY; RISK ASSESSMENT;

EID: 33745480519     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.6.2.179     Document Type: Review

References (122)

1. Achar SA, Kundu S, Norcross WA. Diagnosis of acute coronary syndrome. Am. Fam. Physician 72, 119-126 (2005).
2. Mitra B, Panja M. High sensitive C-reactive protein: a novel biochemical markers and its role in coronary artery disease. J. Assoc. Physicians India 53, 25-32 (2005).
3. Oliveira GH. Novel serologic markers of cardiovascular risk. Curr. Atheroscler. Rep. 7, 148-154 (2005).
4. Shapiro BP, Chen HH, Burnett JC Jr, Redfield MM. Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure. Mayo Clin. Proc. 78, 481-486 (2003).
5. Cowie MR, Jourdain P, Maisel A et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur. Heart J. 24, 1710-1718 (2003).
6. McKie PM, Burnett JC Jr. B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clin. Proc. 80, 1029-1036 (2005).
7. Oyama T, Osaki T, Baba T et al. Molecular genetic tumor markers in non-small cell lung cancer. Anticancer Res. 25, 1193-1196 (2005).
8. Cuperlovic-Culf M, Belacel N, Ouellette RJ. Determination of tumour marker genes from gene expression data. Drug Discov. Today 10, 429-437 (2005).
9. Namazie A, Alavi S, Olapade OI et al. Cyclin D1 amplification and p16 (MTS1/CDK4) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 112, 472-481 (2002).
10. Perrone F, Tamborini E, Dagrada GP et al. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor α gene alterations. Cancer 104, 159-169 (2005).
11. Grafstrom E, Egyhazi S, Ringborg U, Hansson J, Platz A. Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival. Clin. Cancer Res. 11, 2991-2997 (2005).
12. Mitelman F, Johansson B, Mertens F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nature Genet. 36, 331-334 (2004).
13. Salman M, Jhanwar SC, Ostrer H. Will the new cytogenetics replace the old cytogenetics? Clin. Genet. 66, 265-275 (2004).
14. Zhao J, Roth J, Bode-Lesniewska B et al. Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Genes Chromosomes Cancer 34, 48-57 (2002).
15. Shiffman D, Ellis SG, Rowland CM et al. Identification of four gene variants associated with myocardial infarction. Am. J. Hum. Genet. 77, 596-605 (2005).
16. Carlson CS, Eberle MA, Rieder MJ, Smith JD, Kruglyak L, Nickerson DA. Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nature Genet. 33, 518-521 (2003). Defines the number of polymorphisms that need to be genotyped in order to perform a whole-genome association study based on the resequencing of 50 genes in 47 individuals from two populations (African-American and European).
17. Gabriel SB, Schaffner SF, Nguyen H et al. The structure of haplotype blocks in the human genome. Science 296, 2225-2229 (2002). Landmark paper describing the partitioning of the human genome into haplotype blocks and the similarities and differences between European, Asian and African populations.
18. Ahmadi KR, Weale ME, Xue ZY et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nature Genet. 37, 84-89 (2005). Important paper defining a single nucleotide polymorphism tagging set for genes involved in drug metabolism and transport.
19. The International HapMap Consortium. A haplotype map of the human genome. Nature 437, 1299-1320 (2005).
20. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Eng. J. Med. 351, 2817-2826 (2004). Validates a multigene assay for prediction of breast cancer recurrence. This assay is now commercially available.
21. Mehra MR, Kobashigawa J, Hunt S et al. Molecular testing and prediction of clinical outcome in heart transplantation: a prospective multicenter trial. J. Heart Lung Transplant. 23, S106 (2004).
22. Eisen HJ, Deng M, Mehra M et al. Noninvasive molecular screening for acute cardiac rejection: a multicenter prospective clinical study. J. Heart Lung Transplant. 22, S74 (2003).
23. Hammond SM. MicroRNAs as oncogenes. Curr. Opin. Genet. Dev. 16, 4-9 (2005).
24. Bentwich I, Avniel A, Karov Y et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nature Genet. 37, 766-770 (2005). Provides a prediction of the number of microRNAs present in the human genome and highlights the significant role of these molecules.
25. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005).
26. He L, Thomson JM, Hemann MT et al. A microRNA polycistron as a potential human oncogene. Nature 435, 828-833 (2005).
27. Calin GA, Ferracin M, Cimmino A et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353(17), 1793-801 (2005).
28. Neely LA, Patel S, Garver J et al. A single-molecule method for the quantitation of microRNA gene expression. Nature Methods 3(1), 41-6 (2006).
29. Xu XL, Yu J, Zhang HY et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J. Gastroenterol. 10, 3441-3454 (2004).
30. Furuta J, Umebayashi Y, Miyamoto K et al. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci. 95, 962-968 (2004).
31. Brena RM, Huang TH, Plass C. Quantitative assessment of DNA methylation: potential applications for disease diagnosis, classification, and prognosis in clinical settings. J. Mol. Med.17, 1-13 (2006). Good review of DNA methylation biomarkers and technologies.
32. Rakyan VK, Hildmann T, Novik KL et al. DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome project. PLoS Biol. 2, e405 (2004).
33. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nature Rev. Cancer 4, 707-717 (2004).
34. Sidransky D. Emerging molecular markers of cancer. Nature Rev. Cancer 2, 210-219 (2002).
35. Merrick BA, Bruno ME. Genomic and proteomic profiling for biomarkers and signature profiles of toxicity. Curr. Opin. Mol. Ther. 6, 600-607 (2004).
36. LaBaer J, Ramachandran N. Protein microarrays as tools for functional proteomics. Curr. Opin. Chem. Biol. 9, 14-19 (2005).
37. Miller JC, Zhou H, Kwekel J et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3, 56-63 (2003).
38. Beernink HT, Nock S. Challenges facing the development and use of protein chips to analyze the phosphoproteome. Expert Rev. Proteomics 2, 487-497 (2005).
39. Robbins RJ, Villanueva J, Tempst P. Distilling cancer biomarkers from the serum peptidome: high technology reading of tea leaves or an insight to clinical systems biology? J. Clin. Oncol. 23, 4835-4837 (2005).
40. Schulte I, Tammen H, Selle H, Schulz-Knappe P. Peptides in body fluids and tissues as markers of disease. Expert Rev. Mol. Diagn. 5, 145-157 (2005).
41. Tammen H, Schulte I, Hess R et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 5, 3414-3422 (2005).
42. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002). Important paper that describes the first use of a proteomic signature of ovarian cancer.
43. Wang X, Yu J, Sreekumar A et al. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 353, 1224-1235 (2005).
44. Nielsen J, Oliver S. The next wave in metabolome analysis. Trends Biotechnol. 23, 544-546 (2005).
45. Nicholson JK, Wilson ID. Understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nature Rev. Drug Discov. 2, 668-676 (2003). Good overview of the use of metabonomics to elucidate complex gene-environment interactions through a systems biology approach.
46. Dettmer K, Hammock BD. Metabolomics - a new exciting field within the "omics" sciences. Environ. Health Perspect. 112, A396-A397 (2004).
47. Fiehn O. Metabolomics - the link between genotypes and phenotypes. Plant Mol. Biol. 48, 155-171 (2002).
48. Weckwerth W. Metabolomics in systems biology. Annu. Rev. Plant Biol. 54, 669-689 (2003).
49. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nature Rev. Cancer 4, 551-561 (2004).
50. Brindle JT, Antti H, Holmes E et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H-NMR-based metabonomics. Nature Med. 8, 1439-1445 (2002).
51. Keun HC. Metabonomic modeling of drug toxicity. Pharmacol. Ther. 109(1-2), 92-106 (2005).
52. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nature Rev. Drug Discov. 1, 153-161 (2002).
53. de Vries BB, Pfundt R, Leisink M et al. Diagnostic genome profiling in mental retardation. Am. J. Hum. Genet. 77, 606-616 (2005).
54. Fishman A, Shalom-Paz E, Fejgin M, Gaber E, Altaras M, Amiel A. Comparing the genetic changes detected in the primary and secondary tumor sites of ovarian cancer using comparative genomic hybridization. Int. J. Gynecol. Cancer 15, 261-266 (2005).
55. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999). Landmark paper describing the use of gene expression patterns to classify cancer subtypes.
56. Sorlie T, Perou C, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869-10874 (2001).
57. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
58. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
59. Zhang Z, Bast RC Jr, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64, 5882-5890 (2004).
60. Lawrence RW, Evans DM, Cardon LR. Prospects and pitfalls in whole genome association studies. Philos. Trans. R. Soc. Lond. B, Biol. Sci. 360, 1589-1595 (2005).
61. Reich D, Patterson N, Jager PL et al. A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. Nature Genet. 37, 1113-1118 (2005). One of the first studies to demonstrate the benefits of whole-genome admixture scans to define loci for complex diseases.
62. Tamiya G, Shinya M, Imanishi T et al. Whole genome association study of rheumatoid arthritis using 27 039 microsatellites. Hum. Mol. Genet. 14, 2305-2321 (2005).
63. Hu N, Wang C, Hu Y et al. Genome-wide association study in esophageal cancer using GeneChip mapping 10K array. Cancer Res. 65, 2542-2546 (2005).
64. Cui JW, Wang J, He K et al. Proteomic analysis of human acute leukemia cells: insight into their classification. Clin. Cancer Res. 10, 6887-6896 (2004).
65. Becker S, Cazares LH, Watson P et al. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann. Surg. Oncol. 11, 907-914 (2004).
66. Armstrong SA, Staunton JE, Silverman LB et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genet. 30, 41-47 (2002).
67. Yeoh EJ, Ross ME, Shurtleff SA et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133-143 (2002).
68. Bullinger L, Dohner K, Bair E et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350, 1605-1616 (2004).
69. Luhe A, Suter L, Ruepp S, Singer T, Weiser T, Albertini S. Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit? Mutat. Res. 575, 102-115 (2005).
70. Salter AH. Large-scale databases in toxicogenomics. Pharmacogenomics 6, 749-754 (2005).
71. Wilkinson GR. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352, 2211-2221 (2005). Comprehensive review of role of cytochrome P450 enzymes and impact of genetic variation in drug metabolism and response.
72. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther. Drug. Monit. 26, 186-191 (2004).
73. Butcher NJ, Boukouvala S, Sim E, Minchin RF. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J. 2, 30-42 (2002).
74. Chen JS, Coustan-Smith E, Suzuki T et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 97, 2115-2120 (2001).
75. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Eng. J. Med. 350, 2129-2139 (2004).
76. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
77. Holleman A, Cheok MH, den Boer ML et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Eng. J. Med. 351, 533-542 (2004).
78. Kaput J, Rodriguez RL. Nutritional genomics: the next frontier in the postgenomic era. Physiol. Genomics 16, 166-177 (2004).
79. Cameron-Smith D, Burke LM, Angus DJ et al. A short-term, high-fat diet upregulates lipid metabolism and gene expression in human skeletal muscle. Am. J. Clin. Nutr. 77, 313-318 (2003).
80. Mutch DM, Wahli W, Williamson G. Nutrigenomics and nutrigenetics: the emerging faces of nutrition. FASEB J. 19(12), 1602-16 (2005). Good review of the emerging field of nutrigenomics.
81. Lacasana-Navarro M, Galvan-Portillo M, Chen J et al. Methylenetetrahydrofolate reductase 677C>T polymorphism and gastric cancer susceptibility in Mexico. Eur. J. Cancer (2006) (In Press).
82. Wang L, Miao X, Tan W et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer. Clin. Gastroenterol. Hepatol. 3(8), 743-751 (2005).
83. Van Guelpen BR, Wiren SM, Bergh AR et al. Polymorphisms of methylenetetrahydrofolate reductase and the risk of prostate cancer: a nested case-control study. Eur. J. Cancer Prev. 15(1), 46-50 (2006).
84. Karagas MR, Park S, Nelson HH et al. Methylenetetrahydrofolate reductase (MTHFR) variants and bladder cancer: a population-based case-control study. Int. J. Hyg. Environ. Health. 208(5), 321-327 (2005).
85. Krajinovic M, Lamothe S, Labuda D et al. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 103(1), 252-257 (2004).
86. Brazma A, Hemingway P, Quackenbush J et al. Minimum information about a microarray experiment (MIAME) - toward standards for microarray data. Nature Genet. 29, 365-371 (2001). Important paper that set standards for publication of microarray data.
87. Seibert V, Ebert MPA, Buschmann T. Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry. Brief Funct. Genomics Proteomics 4, 16-26 (2005).
88. Levy SE, Statnikov A, Aliferis C. Biomarker selection from high-dimensionality data. Microarray Technol. (Suppl. Pharmaceut. Discov.) 37-44 (2005).
89. Valafar F. Pattern recognition techniques in microarray data analysis. Ann. NY Acad. Sci. 980, 41-64 (2002).
90. West M, Blanchette C, Dressman H et al. Predicting clinical status of human breast cancer by using gene expression profiles. Proc. Natl Acad. Sci. USA 98, 11462-11467 (2001).
91. Efron B, Tibshirani R. Empirical Bayes methods and false discovery rates for microarrays. Genet. Epidemiol. 23, 70-86 (2002).
92. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet. Med. 4, 45-61 (2002). Comprehensive analysis of genetic association studies, noting the importance of careful study design and validation.
93. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nature Genet. 29, 306-309 (2001).
94. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20, 777-785 (2004).
95. Pusztai L, Ayers M, Stec J et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin. Cancer Res. 9, 2406-2415 (2003).
96. Koike Folgueira MA, Carraro DM, Brentani H et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin. Cancer Res. 11, 7434-7443 (2005).
97. Mian S, Ugurel S, Parkinson E et al. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J. Clin. Oncol. 23, 5088-5093 (2005).
98. Constans A. Rethinking clinical proteomics. The Scientist 19, 20-21 (2005).
99. Gordon GJ, Rockwell GN, Godfrey, PA et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin. Cancer Res. 11, 4406-4414 (2005).
100. Watanabe A, Cornelison R, Hostetter G. Tissue microarrays: applications in genomic research. Expert Rev. Mol. Diagn. 5, 171-181 (2005).
101. Xie H-G, Kim RB, Wood AJJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850 (2001).
102. Taylor JSW, Ellis GR. Racial differences in responses to drug treatment. Am. J. Cardiovasc. Drugs 2(6), 389-399 (2002).
103. Bjornsson TD, Wagner JA, Donahue SR et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J. Clin. Pharmacol. 43, 943-967 (2003).
104. Service RF. Going from genome to pill. Science 308, 1858-1860 (2005).
105. Huntjens DR, Danhof M, Della Pasqua OE. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford) 44, 846-859 (2005).
106. Kricka LJ, Master SR. Validation and quality control of protein microarray-based analytical methods. Methods Mol. Med. 114, 233-255 (2005).
107. Csako G. Present and future of rapid and/or high-throughput methods for nucleic acid testing. Clin. Chim. Acta 363(1-2), 6-31 (2005).
108. Zu Y, Steinberg SM, Campo E et al. Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. Leuk. Lymphoma 46, 693-701 (2005).
109. Wilkins-Haug L, Hill LD, Power ML, Holzman GB, Schulkin J. Gynecologists' training, knowledge, and experiences in genetics: a survey. Obstet. Gynecol. 95, 421-424 (2000).
110. Metcalfe S, Hurworth R, Newstead J, Robins R. Needs assessment study of genetics education for general practitioners in Australia. Genet. Med. 4, 71-77 (2002).
111. Gurwitz D, Weizman A, Rehavi M. Education: teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol. Sci. 24, 122-125 (2003).
112. Frueh FW, Gurwitz D. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 5, 571-579 (2004).
113. Smith RA, Saslow D, Sawyer KA et al. American Cancer Society Guidelines for breast cancer screening: update 2003. CA Cancer J. Clin. 53, 141-169 (2003).
114. Notice of Intent; Genetic Testing Under the Clinical Laboratory Improvement Amendments. 65 Fed. Reg. 25928, May 4, (2000)
115. FDA. Analyte Specific Reagents. 21 CFR 864.4020 (2005).
116. Carlson JJ, Henrikson NB, Veenstra DL, Ramsey SD. Economic analyses of human genetics services: a systematic review. Genet. Med. 7, 519-523 (2005).
117. Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 5, 1139-1149 (2004). Nice review of published literature of cost-effectiveness of pharmacogenomic testing.
118. Evans RW, Williams GE, Baron HM et al. The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am. J. Transplant. 5, 1553-1558 (2005).
119. Mitelman F. Atlas of Genetics and Cytogenetics in Oncology and Haematology: Cancer cytogenetics update 2005. www.infobiogen.fr/services/ chromcancer/ Deep/CancerCytogenet2005.html
120. US Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility www.ahrq.gov/clinic/uspstf/uspsbrgen.htm
121. Harper C. Genetic/Molecular IVD Submissions: Presentation at the AMDM FDA OIVD 510(k) Workshop, April (2005) www.fda.gov/cdrh/oivd/presentations/0419 05-harper.ppt
122. Secretary's Advisory Committee on Genetic Testing. Enhancing the oversight of genetic tests: recommendations of the SACGT (July 2000) www4.od.nih.gov/oba/sacgt/reports/oversight _report.pdf